ACS Medicinal Chemistry Letters
Letter
permeability in drug discovery and development settings. Adv. Drug
Delivery Rev. 1997, 23, 3−25.
(25) Hage-Melim, L. I.; Santos, C. B. R.; Poiani, J. G.; de Menezes
Vaidergom, M.; Eduardo, S. M.; Manzolli, E. S.; de Paula da Silva, C.
H. T. Computational Medicinal Chemistry to Design Novel
Phosphoinositide 3-Kinase (PI3K) Alpha Inhibitors in View of
Cancer. Curr. Bioact. Compd. 2014, 10, 147−151.
(26) Tang, H.; Wang, X. S.; Huang, X. P.; Roth, B. L.; Butler, K. V.;
Kozikowski, A. P.; Jung, M.; Tropsha, A. Novel inhibitors of human
histone deacetylase (HDAC) identified by QSAR modeling of known
inhibitors, virtual screening, and experimental validation. J. Chem. Inf.
Model. 2009, 49, 461−476.
(27) Zhao, L.; Xiang, Y.; Song, J.; Zhang, Z. A novel two-step QSAR
modeling work flow to predict selectivity and activity of HDAC
inhibitors. Bioorg. Med. Chem. Lett. 2013, 23, 929−933.
(7) Jorgensen, W. L. Efficient drug lead discovery and optimization.
Acc. Chem. Res. 2009, 42, 724−733.
(8) Morelli, X.; Bourgeas, R.; Roche, P. Chemical and structural
lessons from recent successes in protein−protein interaction inhibition
(2P2I). Curr. Opin. Chem. Biol. 2011, 15, 1−7.
(9) Cain, R. J.; Ridley, A. J. Phosphoinositide 3-kinases in cell
migration. Biol. Cell. 2009, 101, 13−29.
(10) Sawyer, C.; Sturge, J.; Bennett, D. C.; O’Hare, M. J.; Allen, W.
E.; Bain, J.; Jones, G. E.; Vanhaesebroeck, B. Regulation of breast
cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Cancer Res. 2003, 63, 1667−1675.
(11) Price, J. T.; Tiganis, T.; Agarwal, A.; Djakiew, D.; Thompson, E.
W. Epidermal growth factor promotes MDA-MB-231 breast cancer
cell migration through a phosphatidylinositol 3′-kinase and phospho-
lipase C-dependent mechanism. Cancer Res. 1999, 59, 5475−5478.
(12) Akinleye, A.; Avvaru, P.; Furqan, M.; Song, Y.; Liu, D.
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.
J. Hematol. Oncol. 2013, 6, 88−104.
(13) Kim, O.; Jeong, Y.; Lee, H.; Hong, S. S.; Hong, S. Design and
synthesis of imidazopyridine analogues as inhibitors of phosphoinosi-
tide 3-kinase signaling and angiogenesis. J. Med. Chem. 2011, 54,
2455−2466.
(14) Supuran, C. T. Carbonic anhydrases: novel therapeutic
applications for inhibitors and activators. Nat. Rev. Drug Discovery
2008, 7, 168−181.
(15) Pacchiano, F.; Aggarwal, M.; Avvaru, B. S.; Robbins, A. H.;
Scozzafava, A.; McKenna, R.; Supuran, C. T. Selective hydrophobic
pocket binding observed within the carbonic anhydrase II active site
accommodate different 4-substituted-ureidobenzenesulfonamides and
correlate to inhibitor potency. Chem. Commun. 2010, 46, 8371−8373.
(16) Pacchiano, F.; Carta, F.; McDonald, P. C.; Lou, Y.; Vullo, D.;
Scozzafava, A.; Dedhar, S.; Supuran, C. T. Ureido-substituted
benzenesulfonamides potently inhibit carbonic anhydrase IX and
show antimetastatic activity in a model of breast cancer metastasis. J.
Med. Chem. 2011, 54, 1896−1902.
(17) De Ruijter, A. J.; Van Gennip, A. H.; Caron, H. N.; Kemp, S.;
Van Kuilenburg, A. B. Histone deacetylases (HDACs): character-
ization of the classical HDAC family. Biochem. J. 2003, 370, 737−749.
(18) Glaser, K. B.; Li, J.; Staver, M. J.; Wei, R.-Q.; Albert, D. H.;
Davidsen, S. K. Role of Class I and Class II histone deacetylases in
carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 2003,
310, 529−536.
(19) Richon, V. M. Cancer biology: mechanism of antitumour action
of vorinostat (suberoylanilide hydroxamic acid), a novel histone
deacetylase inhibitor. Br. J. Cancer 2006, 95 (Suppl 1), S2−S6.
(20) Wang, H.; Lim, Z. Y.; Zhou, Y.; Ng, M.; Lu, T.; Lee, K.;
Sangthongpitag, K.; Goh, K. C.; Wang, X.; Wu, X.; Khng, H. H.; Goh,
S. K.; Ong, W. C.; Bonday, Z.; Sun, E. T. Acylurea connected straight
chain hydroxamates as novel histone deacetylase inhibitors: Synthesis,
SAR, and in vivo antitumor activity. Bioorg. Med. Chem. Lett. 2010, 20,
3314−3321.
(21) Wang, D. Computational Studies on the Histone Deacetylases
and the Design of Selective Histone Deacetylase Inhibitors. Curr. Top.
Med. Chem. 2009, 9, 241−246.
(22) Ran, T.; Lu, T.; Yuan, H.; Liu, H.; Wang, J.; Zhang, W.; Leng,
Y.; Lin, G.; Zhuang, S.; Chen, Y. A selectivity study on mTOR/PI3Kα
inhibitors by homology modeling and 3D-QSAR. J. Mol. Model. 2012,
18, 171−186.
(23) Melagraki, G.; Afantitis, A.; Sarimveis, H.; Igglessi-Markopoulou,
O.; Supuran, C. T. QSAR study on para-substituted aromatic
sulfonamides as carbonic anhydrase II inhibitors using topological
information indices. Bioorg. Med. Chem. 2006, 14, 1108−1114.
(24) Yang, J. S.; Chun, T.; Nam, K.; Kim, H. M.; Han, G. Structure-
Activity Relationship of Novel Lactam Based Histone Deacetylase
Inhibitors as Potential Anticancer Drugs. Bull. Korean Chem. Soc. 2012,
33, 2063−2066.
E
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX